Safety of Anti-VEGF for Proliferative Diabetic Retinopathy

In this interview from ASRS 2019, Dr. Hani Salehi-Had discusses the safety of anti-VEGF therapy for proliferative diabetic retinopathy. The pooled analysis of 5 DRCR Retina Network studies—protocols I, J, N, S and T—included more than 800 patients; nearly half of the cohort had received anti-VEGF. Overall, investigators found that there was no increased risk of tractional retinal detachment or need for vitrectomy with treatment. This study is important, explains Dr. Salehi-Had, because it supports the safety of anti-VEGF for PDR in a large patient population.

Relevant Financial Disclosures: None